抗CD20单抗治疗儿童原发性肾病综合征的研究进展  

Research progress of the application of anti-CD20 monoclonal antibodies in the treatment of primary nephrotic syndrome in children

作　　者：智元昭 曹璐 张建江[1] Zhi Yuanzhao;Cao Lu;Zhang Jianjiang(Department of Pediatrics,the First Affiliated Hospital of Zhengzhou University,Clinical Diagnosis and Treatment Center of Pediatric Kidney Disease of Henan Province,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院儿科,河南省儿童肾脏病临床诊疗中心,郑州450052

出　　处：《中华实用儿科临床杂志》2022年第23期1833-1836,共4页Chinese Journal of Applied Clinical Pediatrics

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20210280)。

摘　　要：原发性肾病综合征(PNS)是儿童时期常见的肾小球疾病之一,目前抗CD_(20)单抗治疗肾小球疾病是研究热点。抗CD_(20)单抗分3代,以利妥昔单抗(RTX)为代表的第一代抗CD_(20)单抗已被证实在儿童激素依赖/频复发型肾病综合征(SDNS/FRNS)中疗效肯定。以奥法木单抗(OFA)和奥妥珠单抗(OBI)为代表的第二代、第三代抗CD_(20)单抗在儿童PNS中展现出了良好的疗效和安全性。现就抗CD_(20)单抗治疗儿童PNS的临床研究及应用进行综述,以期为治疗儿童PNS提供参考。Primary nephrotic syndrome(PNS)is one of the common glomerular diseases in children.Glomerular disease treatment by anti-CD_(20) monoclonal antibodies is currently a hot topic.There are three generations of anti-CD_(20) monoclonal antibodies.As a representative of the first generation of anti-CD_(20) monoclonal antibodies,Rituximab(RTX)has been proven effective in treating children with steroid-dependent/frequent-relapsing nephrotic syndrome(SDNS/FRNS).Ofatumumab(OFA)and Obinutuzumab(OBI)represent the second-and the third-generation anti-CD_(20) monoclonal antibodies,respectively.OFA and OBI have showed good efficacy and safety in pediatric PNS.In this paper,clinical studies and applications of anti-CD_(20) monoclonal antibodies in the treatment of children with PNS were reviewed,so as to provide a reference for the treatment of PNS in children.

关 键 词：原发性肾病综合征 儿童 抗CD20单抗 

分 类 号：R726.9[医药卫生—儿科]